Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Linagliptin and Metformin Co-administration
NCT02183506Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2005
- Primary completion
- Dec 2005
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of linagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve up to 240 hours and Maximum concentration up to 240 hours. Started Sep 2005; status: completed.
02
Drugs
linagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02183506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02183506.